Lexington, MA, United States of America

Andrew G Plaut

This inventor holds 21 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Glucose Metabolism. Top assignees: Tufts University, New England Medical Center Hospitals. Inc., 1149336 Ontario, Inc.. Active years: 1990-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew G Plaut. Retrieved from https://idiyas.com/inventor/andrew-g-plaut

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 21 

% Patents Active = 81.0


 

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 474(Granted Patents)


Location History:

  • Boston, MA (US) (1995 - 2007)
  • Lexington, MA (US) (1990 - 2015)

Company Filing History:


Years Active: 1990-2015

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Glucose Metabolism
IgA1 Proteases
Dipeptidyl-Aminopeptidase Inhibitors
Combination Therapy
Streptococcus Pneumoniae
Helicobacter Pylori
Protease Inhibitors
Reagents
Abnormal IGA1 Clearance
Deposition Diseases
Emulsifying Agents
21 patents (USPTO):Explore Patents

Title: The Innovative Journey of Andrew G. Plaut

Introduction

Andrew G. Plaut, a distinguished inventor based in Lexington, MA, has made significant contributions to the field of biomedical research. With a remarkable portfolio of 21 patents, Plaut’s work primarily focuses on advancing methods that regulate glucose metabolism and tackle IgA1 deposition diseases. His innovations reflect a deep commitment to improving therapeutic strategies.

Latest Patents

Among Plaut's notable patents is one that outlines methods for regulating glucose metabolism. This invention details the administration of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt to animals. The specificity of the inhibitor, with a Ki for inhibition of DPIV of 10 nM or less, is crucial for effectively increasing the plasma half-life of glucagon-like peptide 1 (GLP-1), while ensuring the immune system remains intact.

Another significant patent involves IGA1 protease polypeptide agents, which are applicable in treating diseases associated with IgA1 deposition. This invention presents methods for screening inhibitors of IgA1 proteases, showcasing Plaut's dedication to innovative solutions in biomedical therapy.

Career Highlights

Throughout his career, Andrew G. Plaut has collaborated with renowned institutions, including New England Medical Center Hospitals and Tufts University. His role in these establishments allowed him to engage in groundbreaking research, pushing the boundaries of current biomedical practices.

Collaborations

Plaut has worked alongside esteemed colleagues, such as William W. Bachovchin and Daniel J. Drucker. These professional relationships have fostered a collaborative environment that has undoubtedly contributed to the success of their research endeavors and the subsequent patents that emerged from their teamwork.

Conclusion

Andrew G. Plaut’s contributions to science through his innovative patents have paved the way for advancements in treating various health conditions. His commitment to research and collaboration underscores the vital role that inventors play in the ongoing quest for better medical solutions. As the landscape of biomedical research evolves, Plaut's work continues to inspire future inventions and innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…